Amyotrophic Lateral Sclerosis (Als) Genetic Variants represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor neurons. Approximately 5-10% of ALS cases are familial, with over 30 genes implicated in disease pathogenesis. This page summarizes the key genetic variants associated with ALS, their molecular mechanisms, clinical implications, and therapeutic relevance.
Amyotrophic lateral sclerosis affects approximately 30,000 Americans, with an incidence of 1-2 per 100,000 people annually. The disease typically presents in mid-life (55-65 years) with progressive muscle weakness, atrophy, and eventual respiratory failure. Genetic factors play a significant role in both familial and sporadic forms of ALS.
The genetic architecture of ALS includes:
The C9orf72 gene on chromosome 9p21 encodes a DENN domain protein involved in endosomal trafficking and autophagy. A hexanucleotide repeat expansion (GGGGCC) in the first intron is the most common genetic cause of ALS, accounting for ~40% of familial ALS and ~5-10% of sporadic ALS.
Key features of C9orf72 expansions:
The expansion leads to:
The SOD1 gene on chromosome 21 encodes copper/zinc superoxide dismutase, a key antioxidant enzyme. Over 180 pathogenic mutations cause ~15-20% of familial ALS, primarily through toxic gain-of-function mechanisms.
Key SOD1 mutations include:
Mechanisms of SOD1 toxicity:
Misfolding and aggregation
Mitochondrial dysfunction
Oxidative stress
Impaired axonal transport
Glial cell dysfunction
SOD1 Gene - Full gene page
The FUS gene on chromosome 16 encodes an RNA-binding protein involved in transcription, splicing, and RNA transport. Mutations cause ~5% of familial ALS, typically with early onset (30-40 years).
Key features:
Nuclear import defect: Mutations impair FUS nuclear localization
RNA processing disruption: Altered splicing and translation
Stress granules: Aberrant stress granule dynamics
Aggregation: FUS-positive inclusions in motor neurons
FUS Gene - Full gene page
The TARDBP gene on chromosome 1 encodes TDP-43, an RNA-binding protein that is the major component of ALS inclusions. While most ALS cases have wild-type TDP-43 pathology, rare mutations cause familial ALS.
Mechanisms:
Protein aggregation
RNA processing defects
Mitochondrial dysfunction
Oxidative stress
TARDBP Gene - Full gene page
The UBQLN2 gene on chromosome X encodes ubiquilin-2, a protein involved in protein degradation through the ubiquitin-proteasome system. X-linked dominant mutations cause ALS with dementia.
The OPTN gene encodes optineurin, involved in autophagy and NF-κB signaling. Mutations cause both ALS and glaucoma.
The TBK1 gene encodes TANK-binding kinase 1, a key regulator of autophagy and innate immunity. Loss-of-function mutations cause ALS/FTD.
The VCP gene mutations cause inclusion body myopathy with early-onset Paget disease and ALS (IBMPFD).
The ANG gene encodes angiogenin, a secreted ribonuclease with roles in stress response and angiogenesis.
Genome-wide association studies have identified multiple ALS risk loci:
| Gene/Region | Chromosome | Odds Ratio | Function |
|---|---|---|---|
| UNC13A | 19p13 | 1.2 | Synaptic vesicle release |
| SOD1 | 21q22 | 1.3 | Antioxidant enzyme |
| ATXN2 | 12q24 | 1.3 | RNA processing |
| DCTN1 | 2p13 | 1.2 | Axonal transport |
| CHCHD10 | 22q11 | 1.5 | Mitochondrial function |
Genetic testing is increasingly important for:
The study of Amyotrophic Lateral Sclerosis (Als) Genetic Variants has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.